Problem

Velorum Therapeutics is addressing a major oncology problem: many cancers appear to depend on free-floating heme, a molecule best known as a component of hemoglobin, to support mitochondrial energy production and rapid growth. The company says tumors can “steal” heme from the blood, creating a metabolic vulnerability that could be particularly valuable in lung cancer, identified in its launch materials as the leading cancer killer. The practical pain is the need for treatments that kill or weaken tumors without harming healthy tissue and that improve the effectiveness of existing therapies.

The main use case is therefore a heme-deprivation cancer therapy, initially focused on lung cancer but potentially applicable across multiple tumor types that share this metabolic dependence. The materials do not provide pricing, market-size, or cost-of-care figures, but they frame the opportunity around an important unmet need: making tumors more vulnerable to radiation, chemotherapy, and immunotherapy while preserving normal cells.

Product / Service

Velorum is developing protein-based cancer drugs designed to remove the heme that tumors need. Rather than directly attacking cancer cells with a conventional cytotoxic mechanism, the drugs are intended to amplify the body’s natural system for clearing free-floating heme. The company says its proteins evolved to capture heme, allowing the therapy to use a biological cleanup mechanism that is already present in the body.

In animal studies, Velorum reports that its drugs were effective against multiple cancers without affecting healthy cells, even at high doses. By starving tumors, the treatment may also weaken them and increase their susceptibility to radiation, chemotherapy, and immunotherapies. The lead program was described as advancing toward first-in-human testing, beginning with lung cancer.

Market

Velorum competes in biotechnology and oncology therapeutics, specifically the emerging area of cancer-metabolism drug discovery. Its stated approach is differentiated around targeting heme biology rather than the more familiar tumor antigens, signaling pathways, or immune mechanisms. The available company and accelerator materials do not name direct competitors, so the relevant comparison set is broader oncology companies developing metabolism-targeted or combination cancer therapies.

The company appears to be pre-commercial and preclinical rather than generating reported product revenue: its disclosed traction consists of Y Combinator backing, patented drug candidates, positive mouse data across multiple cancers, and plans to enter human trials. Velorum was founded in 2023, joined Y Combinator’s Winter 2024 batch, and is listed as an active biotech company in San Francisco. No clinical-trial results, commercial sales, or later-stage financing are identified in the available materials.